Baxter International Inc ( (BAX) ) has released its Q4 earnings. Here is a breakdown of the information Baxter International Inc presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Baxter International Inc., a leading global medtech company, specializes in medical products and therapies, pharmaceuticals, and healthcare systems. Operating in more than 100 countries, the company focuses on delivering innovative solutions to enhance healthcare delivery.
Recently, Baxter reported a modest 1% increase in fourth-quarter sales from continuing operations, totaling $2.75 billion, and a 3% rise in full-year sales, reaching $10.64 billion. The company’s adjusted earnings per share for the fourth quarter and full year surpassed guidance, indicating strong performance despite challenges like Hurricane Helene.
Key financial highlights include a 3% growth in full-year sales and adjusted diluted EPS from continuing operations of $1.89. The sale of Baxter’s Kidney Care business, completed in early 2025, generated $3.4 billion in net proceeds, allowing strategic debt repayment. Baxter also saw significant growth in its Pharmaceuticals segment, with high single-digit sales increases driven by specialty injectables.
Looking ahead, Baxter anticipates 5% to 6% sales growth in 2025 and aims to strengthen its financial position through strategic investments and improved cash flow generation. As the company completes its transformation, it seeks to define a new era of operational efficiency and innovation under new leadership.
